Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 24Genitourinary 12Head & Neck 5Thoracic 4Gynecologic 4Sarcoma 2Gastrointestinal 2Endocrine 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1CNS 1

Conditions

Breast Cancer Survivor 1

Interventions

Biopsy 8Polymerase Chain Reaction 6Peripheral Blood Stem Cell Transplantation 5Epoetin Alfa 5Surveys and Questionnaires 4Sulindac 4Microarray Analysis 4Gene Expression Profiling 4Early Intervention, Educational 4Cyclophosphamide 4Colposcopy 4Cisplatin 4Cetuximab 4Celecoxib 4fludarabine phosphate 3Vaginal Smears 3Selenium 3Pemetrexed 3Methotrexate 3Imiquimod 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3Eflornithine 3Darbepoetin alfa 3Aspirin 3Antilymphocyte Serum 3Whole-Body Irradiation 2Vitamin E 2Videotape Recording 2Tacrolimus 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × High-Energy Shock Waves × Other neoplasm × Clear all
NCT01062542 2018-06-12

Assessment of Ovarian Reserve in Female Cancer Survivors

University Health Network, Toronto

Completed
210 enrolled
BreastOther neoplasm

Breast Cancer Survivor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡